Phase 3 Readout~month
Phase 3 Topline: An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familia
- Indication
- Familial Chylomicronemia Syndrome
Other upcoming events for IONS
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Sa
PDUFA DatePDUFA Date: zilganersen
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients Wit
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Fami
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.